

Anita Deswal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5338012/publications.pdf>

Version: 2024-02-01

169
papers

13,514
citations

31902

53
h-index

22102

113
g-index

183
all docs

183
docs citations

183
times ranked

13740
citing authors

#	ARTICLE	IF	CITATIONS
1	Diuretic Strategies in Patients with Acute Decompensated Heart Failure. <i>New England Journal of Medicine</i> , 2011, 364, 797-805.	13.9	1,363
2	Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1268.	3.8	976
3	Cytokines and Cytokine Receptors in Advanced Heart Failure. <i>Circulation</i> , 2001, 103, 2055-2059.	1.6	903
4	Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome. <i>New England Journal of Medicine</i> , 2012, 367, 2296-2304.	13.9	790
5	Impact of Noncardiac Comorbidities on Morbidity and Mortality in a Predominantly Male Population With Heart Failure and Preserved Versus Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2012, 59, 998-1005.	1.2	578
6	Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2016, 134, e579-e646.	1.6	532
7	Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 2533.	3.8	410
8	Safety and Efficacy of a Soluble P75 Tumor Necrosis Factor Receptor (Enbrel, Etanercept) in Patients With Advanced Heart Failure. <i>Circulation</i> , 1999, 99, 3224-3226.	1.6	367
9	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2020, 76, e159-e240.	1.2	364
10	Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. <i>Circulation</i> , 2019, 140, e294-e324.	1.6	342
11	Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2016, 134, e535-e578.	1.6	285
12	Classification of Heart Failure in the Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation: Heart Failure</i> , 2012, 5, 152-159.	1.6	278
13	Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. <i>Journal of the American Heart Association</i> , 2020, 9, e013757.	1.6	240
14	Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients. <i>Circulation</i> , 2015, 131, 1763-1771.	1.6	239
15	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 1304-1317.	2.6	232
16	Transitions of Care in Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 384-409.	1.6	206
17	Metformin Use and Mortality in Ambulatory Patients With Diabetes and Heart Failure. <i>Circulation: Heart Failure</i> , 2011, 4, 53-58.	1.6	172
18	Relationship of Hemoglobin A1C and Mortality in Heart Failure Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2009, 54, 422-428.	1.2	171

#	ARTICLE	IF	CITATIONS
19	Results of the Randomized Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction Trial (RAAM-PEF). <i>Journal of Cardiac Failure</i> , 2011, 17, 634-642.	0.7	171
20	Biomarkers of inflammation in heart failure. <i>Heart Failure Reviews</i> , 2010, 15, 331-341.	1.7	169
21	Continuous Wearable Monitoring Analytics Predict Heart Failure Hospitalization. <i>Circulation: Heart Failure</i> , 2020, 13, e006513.	1.6	154
22	Quantification of the Myocardial Response to Low-Dose Dobutamine Using Tissue Doppler Echocardiographic Measures of Velocity and Velocity Gradient. <i>American Journal of Cardiology</i> , 1998, 81, 615-623.	0.7	145
23	Experimental and Clinical Basis for the Use of Statins in Patients With Ischemic and Nonischemic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2008, 51, 415-426.	1.2	144
24	Impact of Atrial Fibrillation on Exercise Capacity in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 123-130.	1.6	134
25	Gender Disparities in Evidence-Based Statin Therapy in Patients With Cardiovascular Disease. <i>American Journal of Cardiology</i> , 2015, 115, 21-26.	0.7	134
26	Nutrition, Obesity, and Cachexia in Patients With Heart Failure: A Consensus Statement from the Heart Failure Society of America Scientific Statements Committee. <i>Journal of Cardiac Failure</i> , 2019, 25, 380-400.	0.7	122
27	Impact of race on health care utilization and outcomes in veterans with congestive heart failure. <i>Journal of the American College of Cardiology</i> , 2004, 43, 778-784.	1.2	108
28	Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX) Trial. <i>Circulation: Heart Failure</i> , 2012, 5, 653-659.	1.6	107
29	Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. <i>Journal of Cardiac Failure</i> , 2002, 8, 390-398.	0.7	97
30	N-Terminal Pro-Brain Natriuretic Peptide and Heart Failure Risk Among Individuals With and Without Obesity. <i>Circulation</i> , 2016, 133, 631-638.	1.6	96
31	CARDIAC INVOLVEMENT IN SCLERODERMA. <i>Rheumatic Disease Clinics of North America</i> , 1996, 22, 841-860.	0.8	93
32	Cardiorenal Rescue Study in Acute Decompensated Heart Failure: Rationale and Design of CARRESS-HF, for the Heart Failure Clinical Research Network. <i>Journal of Cardiac Failure</i> , 2012, 18, 176-182.	0.7	91
33	Pre-Morbid Body Mass Index and Mortality After Incident Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2743-2749.	1.2	83
34	Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide: A Biomarker Approach to Predict Heart Failure Risk in the Atherosclerosis Risk in Communities Study. <i>Clinical Chemistry</i> , 2013, 59, 1802-1810.	1.5	82
35	Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities Study. <i>European Heart Journal</i> , 2015, 36, 939-945.	1.0	82
36	Comparison of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction Among Those With Versus Without Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2010, 105, 373-377.	0.7	81

#	ARTICLE	IF	CITATIONS
37	Circulating Levels of Tumor Necrosis Factor Correlate With Indexes of Depressed Heart Rate Variability. <i>Chest</i> , 2003, 123, 716-724.	0.4	80
38	A prospective echocardiographic evaluation of pulmonary hypertension in chronic hemodialysis patients in the United States: prevalence and clinical significance. <i>International Journal of General Medicine</i> , 2010, 3, 279.	0.8	80
39	The role of cytokines in disease progression in heart failure. <i>Current Opinion in Cardiology</i> , 1997, 12, 218-223.	0.8	79
40	Comparison of Morbidity in Women Versus Men With Heart Failure and Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2006, 97, 1228-1231.	0.7	78
41	Obesity as a prognostic factor in chronic symptomatic heart failure. <i>American Heart Journal</i> , 2005, 150, 1233-1239.	1.2	77
42	An overview of tumor necrosis factor $\hat{\pm}$ and the failing human heart. <i>Current Opinion in Cardiology</i> , 1999, 14, 206.	0.8	77
43	Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. <i>Circulation: Heart Failure</i> , 2015, 8, 1052-1058.	1.6	70
44	Prognostic Significance of Hyponatremia Among Ambulatory Patients With Heart Failure and Preserved and Reduced Ejection Fractions. <i>American Journal of Cardiology</i> , 2014, 113, 1834-1838.	0.7	67
45	Effects of Sildenafil on Ventricular and Vascular Function in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2015, 8, 533-541.	1.6	64
46	Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis. <i>JAMA Cardiology</i> , 2021, 6, 1329.	3.0	64
47	Frequency and Practice-Level Variation in Inappropriate Aspirin Use for the Primary Prevention of Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2015, 65, 111-121.	1.2	63
48	Incidence and Onset of Severe Cardiac Events After Radiotherapy for Esophageal Cancer. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1682-1690.	0.5	63
49	Racial variations in quality of care and outcomes in an ambulatory heart failure cohort. <i>American Heart Journal</i> , 2006, 152, 348-354.	1.2	61
50	New Therapeutics for Chronic Heart Failure. <i>Annual Review of Medicine</i> , 2002, 53, 59-74.	5.0	60
51	Association of systolic blood pressure with mortality in patients with heart failure with reduced ejection fraction: A complex relationship. <i>American Heart Journal</i> , 2011, 161, 567-573.	1.2	60
52	Circulating Collagen Biomarkers as Indicators of Disease Severity in Pulmonary Arterial Hypertension. <i>JACC: Heart Failure</i> , 2014, 2, 412-421.	1.9	58
53	Short-Term Global Cardiovascular Disease Risk Prediction in Older Adults. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2527-2536.	1.2	56
54	Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors. <i>Arthritis and Rheumatology</i> , 2021, 73, 866-874.	2.9	56

#	ARTICLE	IF	CITATIONS
55	Reduction in BNP Levels With Treatment of Decompensated Heart Failure and Future Clinical Events. <i>Journal of Cardiac Failure</i> , 2009, 15, 293-299.	0.7	55
56	Provider Type and Quality of Outpatient Cardiovascular Disease Care. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1803-1812.	1.2	54
57	Patients with severe chronic kidney disease benefit from early revascularization after acute coronary syndrome. <i>International Journal of Cardiology</i> , 2013, 168, 3741-3746.	0.8	52
58	Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. <i>European Journal of Heart Failure</i> , 2021, 23, 1725-1735.	2.9	51
59	Angiotensin-Receptor Blockade in Acute Myocardial Infarction – A Matter of Dose. <i>New England Journal of Medicine</i> , 2003, 349, 1963-1965.	13.9	46
60	Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis. <i>Circulation</i> , 2021, 144, 1521-1523.	1.6	44
61	The July effect and cardiac surgery: the effect of the beginning of the academic cycle on outcomes. <i>American Journal of Surgery</i> , 2008, 196, 720-725.	0.9	43
62	BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study. <i>International Journal of Cardiology</i> , 2017, 233, 61-66.	0.8	42
63	Recent Innovations, Modifications, and Evolution of ACC/AHA Clinical Practice Guidelines: An Update for Our Constituencies: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019, 139, e879-e886.	1.6	41
64	Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Peripheral Arterial and Ischemic Cerebrovascular Disease Compared to Veterans With Coronary Heart Disease. <i>American Journal of Cardiology</i> , 2016, 118, 1144-1149.	0.7	39
65	Effects of Spironolactone Treatment in Elderly Women With Heart Failure and Preserved Left Ventricular Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2014, 20, 560-568.	0.7	38
66	Echocardiographic Changes During Treatment of Acute Decompensated Heart Failure: Insights From the ESCAPE Trial. <i>Journal of Cardiac Failure</i> , 2012, 18, 792-798.	0.7	35
67	Comparison of outcomes of white versus black patients hospitalized with heart failure and preserved ejection fraction**The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.. <i>American Journal of Cardiology</i> , 2004, 94, 1003-1007.	0.7	34
68	Diastolic dysfunction and diastolic heart failure: Mechanisms and epidemiology. <i>Current Cardiology Reports</i> , 2005, 7, 178-183.	1.3	33
69	The Impact of Thiazolidinedione Use on Outcomes in Ambulatory Patients With Diabetes Mellitus and Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 50, 32-36.	1.2	33
70	2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 162, e23-e106.	0.4	33
71	New Predictive Models of Heart Failure Mortality Using Time-Series Measurements and Ensemble Models. <i>Circulation: Heart Failure</i> , 2011, 4, 456-462.	1.6	31
72	Association of NT-ProBNP, Blood Pressure, and Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2021, 77, 559-571.	1.2	31

#	ARTICLE	IF	CITATIONS
73	The Potentially Modifiable Burden of Incident Heart Failure Due to Obesity: The Atherosclerosis Risk in Communities Study. <i>American Journal of Epidemiology</i> , 2010, 172, 781-789.	1.6	30
74	Health Care Resource Utilization for Outpatient Cardiovascular Disease and Diabetes Care Delivery Among Advanced Practice Providers and Physician Providers in Primary Care. <i>Population Health Management</i> , 2018, 21, 209-216.	0.8	30
75	Senescence-Associated Secretory Phenotype as a Hinge Between Cardiovascular Diseases and Cancer. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 763930.	1.1	30
76	Trials within Trials. <i>Contemporary Clinical Trials</i> , 2001, 22, 605-619.	2.0	29
77	Translation of clinical trial results into practice: Temporal patterns of β -blocker utilization for heart failure at hospital discharge and during ambulatory follow-up. <i>American Heart Journal</i> , 2007, 153, 515-522.	1.2	29
78	Predicting Quality of Life in Veterans with Heart Failure: The Role of Disease Severity, Depression, and Comorbid Anxiety. <i>Behavioral Medicine</i> , 2010, 36, 70-76.	1.0	27
79	Modern Radiotherapy and Risk of Cardiotoxicity. <i>Chemotherapy</i> , 2020, 65, 65-76.	0.8	27
80	Obesity and the paradox of mortality and heart failure hospitalization in heart failure with preserved ejection fraction. <i>International Journal of Obesity</i> , 2020, 44, 1561-1567.	1.6	26
81	COVID-19 myocarditis and long-term heart failure sequelae. <i>Current Opinion in Cardiology</i> , 2021, 36, 234-240.	0.8	26
82	New Insights into Mechanisms of Action of Carvedilol Treatment in Chronic Heart Failure Patients—A Matter of Time for Contractility. <i>Journal of Cardiac Failure</i> , 2012, 18, 183-193.	0.7	24
83	Worsening renal function is not associated with response to treatment in acute heart failure. <i>International Journal of Cardiology</i> , 2013, 167, 1912-1917.	0.8	23
84	Recurrent low-level Troponin I elevation is a worse prognostic indicator than occasional injury pattern in patients hospitalized with heart failure. <i>International Journal of Cardiology</i> , 2013, 166, 394-398.	0.8	23
85	Regional Variations in Heart Failure Quality and Outcomes: Get With The Guidelines—Heart Failure Registry. <i>Journal of the American Heart Association</i> , 2021, 10, e018696.	1.6	23
86	Impact of Alpha 1-Adrenergic Antagonist Use for Benign Prostatic Hypertrophy on Outcomes in Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2009, 104, 270-275.	0.7	22
87	Guideline-Directed Medication Use in Patients With Heart Failure With Reduced Ejection Fraction in India: American College of Cardiology's PINNACLE India Quality Improvement Program. <i>Clinical Cardiology</i> , 2016, 39, 145-149.	0.7	22
88	Spironolactone in pulmonary arterial hypertension: results of a crossover study. <i>Pulmonary Circulation</i> , 2020, 10, 1-8.	0.8	22
89	Decreasing Body Temperature Predicts Early Rehospitalization in Congestive Heart Failure. <i>Journal of Cardiac Failure</i> , 2008, 14, 489-496.	0.7	21
90	Role and Optimal Dosing of Angiotensin-Converting Enzyme Inhibitors in Heart Failure. <i>Cardiology Clinics</i> , 2008, 26, 1-14.	0.9	20

#	ARTICLE	IF	CITATIONS
91	Cardiovascular Toxicities of Androgen Deprivation Therapy. Current Treatment Options in Oncology, 2021, 22, 47.	1.3	20
92	Digoxin treatment in heart failure – Unveiling risk by cluster analysis of DIG data. International Journal of Cardiology, 2011, 150, 264-269.	0.8	19
93	Lifestyle Modification with Diet and Exercise in Obese Patients with Heart Failure – A Pilot Study. Journal of Obesity & Weight Loss Therapy, 2012, 02, 1-8.	0.1	19
94	Myocardial Injury, Obesity, and the Obesity Paradox. JACC: Heart Failure, 2017, 5, 56-63.	1.9	19
95	Predictors of Mortality by Sex and Race in Heart Failure With Preserved Ejection Fraction: ARIC Community Surveillance Study. Journal of the American Heart Association, 2020, 9, e014669.	1.6	19
96	Mortality After Hospitalization for Heart Failure in Blacks Compared to Whites. American Journal of Cardiology, 2010, 105, 694-700.	0.7	18
97	Revascularization improves mortality in elderly patients with acute myocardial infarction complicated by cardiogenic shock. International Journal of Cardiology, 2014, 172, 239-241.	0.8	18
98	Effects of Vesnarinone on Peripheral Circulating Levels of Cytokines and Cytokine Receptors in Patients With Heart Failure. Chest, 2001, 120, 453-459.	0.4	17
99	Comparison of Frequency of Cardiovascular Events and Mortality in Patients With Heart Failure Using Versus Not Using Cocaine. American Journal of Cardiology, 2017, 119, 2030-2034.	0.7	17
100	Nucleus-mitochondria positive feedback loop formed by ERK5 S496 phosphorylation-mediated poly (ADP-ribose) polymerase activation provokes persistent pro-inflammatory senescent phenotype and accelerates coronary atherosclerosis after chemo-radiation. Redox Biology, 2021, 47, 102132.	3.9	17
101	The Impact of Radiation Dose to Heart Substructures on Major Coronary Events and Patient Survival after Chemoradiation Therapy for Esophageal Cancer. Cancers, 2022, 14, 1304.	1.7	17
102	Variation by race in factors contributing to heart failure hospitalizations. Journal of Cardiac Failure, 2005, 11, 23-29.	0.7	16
103	Acute myocardial infarction in a high-risk cancer population: Outcomes following conservative versus invasive management. International Journal of Cardiology, 2020, 313, 1-8.	0.8	16
104	Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure. Pharmacoepidemiology and Drug Safety, 2012, 21, 233-240.	0.9	15
105	Depression and Anxiety in Ambulatory Patients With Heart Failure. Psychosomatics, 2009, 50, 592-598.	2.5	15
106	Radiation-Induced Cardiovascular Disease: Mechanisms, Prevention, and Treatment. Current Oncology Reports, 2022, 24, 543-553.	1.8	15
107	Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils. Journal of the National Cancer Institute, 2021, 113, 513-522.	3.0	13
108	The Metabolic Syndrome and Mortality in an Ethnically Diverse Heart Failure Population. Journal of Cardiac Failure, 2008, 14, 590-595.	0.7	12

#	ARTICLE	IF	CITATIONS
109	Association Between Preoperative Diuretic Use and In-hospital Outcomes After Cardiac Surgery. <i>Cardiovascular Therapeutics</i> , 2013, 31, 291-297.	1.1	12
110	Anti-angiotensin Therapy: New Perspectives. <i>Cardiology Clinics</i> , 2007, 25, 573-580.	0.9	11
111	Relation Between Playing Position and Coronary Artery Calcium Scores in Retired National Football League Players. <i>American Journal of Cardiology</i> , 2014, 114, 1836-1840.	0.7	11
112	Complex antithrombotic therapy: determinants of patient preference and impact on medication adherence. <i>Patient Preference and Adherence</i> , 2015, 9, 1657.	0.8	11
113	Association of clonal hematopoiesis mutations with clinical outcomes: A systematic review and meta-analysis. <i>American Journal of Hematology</i> , 2022, 97, 411-420.	2.0	11
114	Obesity, Leptin, and Incident Heart Failure. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1878-1880.	1.2	10
115	Acute Kidney Injury With Ventricular Assist Device Placement: National Estimates of Trends and Outcomes. <i>American Journal of Kidney Diseases</i> , 2019, 74, 650-658.	2.1	10
116	Cardiovascular Complications of Chimeric Antigen Receptor T-Cell Therapy: The Cytokine Release Syndrome and Associated Arrhythmias. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 113-120.	0.6	10
117	Prevention of "Failure". <i>Circulation</i> , 2018, 137, 106-108.	1.6	9
118	Aldosterone Receptor Blockade in Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2018, 14, 525-535.	1.0	9
119	Obesity and Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2021, 17, 345-356.	1.0	9
120	Long-Term Results of Coronary Artery Bypass Grafting in Patients With Ischemic Cardiomyopathy: The Impact of Renal Insufficiency and Noncardiac Vascular Disease. <i>Journal of Cardiac Failure</i> , 2005, 11, 206-212.	0.7	8
121	COVID-19 and Cardiovascular Health Among Patients with Cancer. <i>Current Cardiology Reports</i> , 2020, 22, 171.	1.3	8
122	Anemia in Cardiovascular Disease: Marker of Disease Severity or Disease-modifying Therapeutic Target?. <i>Current Atherosclerosis Reports</i> , 2021, 23, 61.	2.0	8
123	Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. <i>Open Heart</i> , 2021, 8, e001849.	0.9	8
124	Advances in the treatment of heart failure with a preserved ejection fraction. <i>Current Opinion in Cardiology</i> , 2008, 23, 233-240.	0.8	7
125	Trends in Left Ventricular Assist Device Implantation and Associated Mortality Among Patients With and Without ESRD. <i>American Journal of Kidney Diseases</i> , 2018, 72, 620-622.	2.1	7
126	Iron deficiency and iron therapy in heart failure and chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 508-514.	1.0	7

#	ARTICLE	IF	CITATIONS
127	Readmissions after Acute Kidney Injury during Left Ventricular Assist Device Implantation Hospitalization. <i>American Journal of Nephrology</i> , 2020, 51, 172-181.	1.4	7
128	Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 315-330.	0.7	7
129	The fragility of cardiovascular clinical trial results. <i>Journal of Cardiac Failure</i> , 2002, 8, 247-253.	0.7	6
130	Aldosterone receptor blockers in the treatment of heart failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2004, 6, 327-334.	0.4	6
131	Incident Cancer in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 62, 887-888.	1.2	6
132	De Novo Heart Failure After Kidney Transplantation: Trends in Incidence and Outcomes. <i>American Journal of Kidney Diseases</i> , 2018, 72, 223-233.	2.1	6
133	Lenalidomide-Induced Myocarditis, Rare But Possibly Fatal Toxicity of a Commonly Used Immunotherapy. <i>JACC: Case Reports</i> , 2020, 2, 2095-2100.	0.3	6
134	Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure. <i>Vascular Health and Risk Management</i> , 2010, 6, 449-55.	1.0	6
135	Cardio-Oncology: Learning From the Old, Applying to the New. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 601893.	1.1	5
136	Treatment of patients with heart failure and preserved ejection fraction. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2008, 10, 516-528.	0.4	4
137	Coronary Artery Disease Performance Measures and Statin Use in Patients With Recent Percutaneous Coronary Intervention or Recent Coronary Artery Bypass Grafting (from the NCDR PINNACLE Registry). <i>American Journal of Cardiology</i> , 2015, 115, 1013-1018.	0.7	4
138	Isolated Cardiac Amyloidosis: An Enigma Unravelling. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 11, 53.	0.5	4
139	Acute coronary syndrome in patients with cancer. <i>Expert Review of Cardiovascular Therapy</i> , 2022, 20, 275-290.	0.6	4
140	Response to Letter Regarding Article, "Effects of Sildenafil on Ventricular and Vascular Function in Heart Failure With Preserved Ejection Fraction". <i>Circulation: Heart Failure</i> , 2015, 8, 840-840.	1.6	3
141	Heart Failure With Reduced Ejection Fraction and Renal Dysfunction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2905-2907.	1.2	2
142	Association of Body Mass Index With Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Cardiovascular Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e004817.	0.9	2
143	Rate of Progression of Aortic Stenosis in Patients With Cancer. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 644264.	1.1	2
144	Clinical Impact of Cardiovascular Magnetic Resonance in Cancer Patients With Suspected Cardiomyopathy. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 734820.	1.1	2

#	ARTICLE	IF	CITATIONS
145	Review: In HF with reduced EF, nurse-led titration of HF drugs reduces hospitalizations and mortality. <i>Annals of Internal Medicine</i> , 2016, 164, JC41.	2.0	1
146	Ularitide in Acute Heart Failure. <i>Current Emergency and Hospital Medicine Reports</i> , 2018, 6, 17-23.	0.6	1
147	In AF and HF, catheter ablation vs medical therapy reduced mortality and hospitalization for worsening HF. <i>Annals of Internal Medicine</i> , 2018, 168, JC55.	2.0	1
148	NT-proBNP-guided and conventional therapies did not differ for readmission or mortality in acute decompensated HF. <i>Annals of Internal Medicine</i> , 2018, 169, JC21.	2.0	1
149	Understanding by General Providers of the Echocardiogram Report. <i>American Journal of Cardiology</i> , 2019, 124, 296-302.	0.7	1
150	An overview of a different type of cardio-oncology gathering: summary of the COMP (cardio-oncology multidisciplinary practice) meeting held in Houston Texas, January 2020. <i>Cardio-Oncology</i> , 2020, 6, 20.	0.8	1
151	Geographical Differences in Cardiovascular Comorbidities and Outcomes of COVID-19 Hospitalized Patients in the USA. <i>Cardiology</i> , 2021, 146, 481-488.	0.6	1
152	In older patients with permanent AF and HF, digoxin and bisoprolol did not differ for QoL at 6 mo. <i>Annals of Internal Medicine</i> , 2021, 174, JC69.	2.0	1
153	Can We Mitigate Coronary Heart Disease Risk in Patients with Cancer?. <i>Current Atherosclerosis Reports</i> , 2022, 24, 599-606.	2.0	1
154	Myocardial Dysfunction in Patients with Cancer. <i>Heart Failure Clinics</i> , 2022, 18, 361-374.	1.0	1
155	Perils of the Random Experiment. <i>American Journal of Therapeutics</i> , 2003, 10, 112-121.	0.5	0
156	Can valsartan reduce the occurrence of atrial fibrillation in heart failure patients?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 502-503.	3.3	0
157	Role and Optimal Dosing of Angiotensin-Converting Enzyme Inhibitor Therapy. <i>Heart Failure Clinics</i> , 2005, 1, 25-37.	1.0	0
158	β-Blockers in systolic heart failure: Do physicians need more courage?. <i>American Heart Journal</i> , 2007, 154, e25.	1.2	0
159	Statin Use and Survival in Patients with Ischemic and Non-Ischemic Heart Failure: Results of a Meta-Analysis. <i>Journal of Cardiac Failure</i> , 2007, 13, S78.	0.7	0
160	Hemoglobin Drop during Hospitalization Predicts Poor Survival in Anemic Patients with Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2009, 15, S97-S98.	0.7	0
161	Lack of Association of Changes in BNP with Cardiorenal Syndrome during Treatment of Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2011, 17, S91.	0.7	0
162	SAFETY AND EFFECTIVENESS OF BALLOON AORTIC VALVULOPLASTY FOR SEVERE AORTIC STENOSIS IN THE CONTEMPORARY ERA. <i>Journal of the American College of Cardiology</i> , 2014, 63, A1746.	1.2	0

#	ARTICLE	IF	CITATIONS
163	Differential Response to Low Dose Dopamine or Nesiritide in Patients with Acute Heart Failure and Renal Dysfunction in Accordance to LV EF: Sub-Group Analysis of the ROSE AHF Trial. <i>Journal of Cardiac Failure</i> , 2014, 20, S94.	0.7	0
164	Do Biomarkers Improve Short-term Risk Prediction of Global Cardiovascular Events in Older Adults? Insights from the Atherosclerosis Risk in Communities Study*. <i>Journal of Clinical Lipidology</i> , 2018, 12, 525-526.	0.6	0
165	BASELINE RIGHT VENTRICULAR FUNCTION IS ASSOCIATED WITH REDUCED NEED OF DIURETICS IN PATIENTS WITH HEART FAILURE WITH IMPROVED EJECTION FRACTION. <i>Journal of the American College of Cardiology</i> , 2019, 73, 786.	1.2	0
166	In heart failure, adding empagliflozin to medical therapy reduced a composite of CV death or HF hospitalization. <i>Annals of Internal Medicine</i> , 2020, 173, JC51.	2.0	0
167	Classification of Pulmonary Hypertension in CKD. <i>American Journal of Kidney Diseases</i> , 2020, 75, 690-692.	2.1	0
168	Asymptomatic left ventricular dysfunction: an overlooked part of the continuum of heart failure. <i>Heart Failure Monitor</i> , 2002, 3, 42-8.	0.7	0
169	Review: B-type natriuretic peptide consistently predicts death and cardiovascular events in heart failure. <i>ACP Journal Club</i> , 2005, 143, 53.	0.1	0